Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder
- First Online:
- Cite this article as:
- Roitman, P., Mechoulam, R., Cooper-Kazaz, R. et al. Clin Drug Investig (2014) 34: 587. doi:10.1007/s40261-014-0212-3
- 559 Downloads
Background and Objectives
Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ9-tetrahydrocannabinol (THC) for chronic PTSD.
Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ9-THC twice a day as add-on treatment.
There were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.
Orally absorbable Δ9-THC was safe and well tolerated by patients with chronic PTSD.